Cutera (NASDAQ:CUTR) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a research report released on Sunday morning. The brokerage issued a sell rating on the medical device company’s stock.

Cutera Price Performance

NASDAQ:CUTR opened at $0.57 on Friday. Cutera has a 12 month low of $0.28 and a 12 month high of $4.97. The firm has a market capitalization of $11.48 million, a PE ratio of -0.09 and a beta of 1.31. The business’s fifty day moving average price is $0.41 and its 200 day moving average price is $0.79.

Institutional Investors Weigh In On Cutera

Several institutional investors have recently added to or reduced their stakes in CUTR. Squarepoint Ops LLC increased its stake in Cutera by 164.5% in the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after purchasing an additional 70,870 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Cutera by 14.2% in the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after buying an additional 35,248 shares in the last quarter. Finally, Ground Swell Capital LLC purchased a new position in shares of Cutera in the 2nd quarter valued at $37,000. Hedge funds and other institutional investors own 90.70% of the company’s stock.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.